lutions that meet their diverse and evolving needs, and our science is built to deliver exactly that.”







































BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.



















GLOBAL HEAD OF R&D AND CORPORATE DEVELOPMENT



















GALDERMA































Therapeutic Dermatology: Latest updates across atopic dermatitis and acne

Four presentations on Nemluvio (nemolizumab), the first approved monoclonal antibody that specifically target
=*=*=*=*=*=
当前为第3/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页